Location History:
- Moscow reg., RU (2013)
- Podosinki, RU (2014)
Company Filing History:
2 out of 832,880 Years Active: 2013-2014
Title: Madina Georgievna Kadieva: A Pioneer in Serotonin Receptor Research
Introduction: Madina Georgievna Kadieva, an innovative inventor based in Podosinki, Russia, has made significant contributions to the field of pharmaceuticals through her research and inventions related to serotonin 5-HT6 receptor antagonists. With a remarkable portfolio of two patents, her work emphasizes the development of novel compounds aimed at treating central nervous system diseases.
Latest Patents: Her latest patents include "Substituted methyl amines, serotonin 5-HT6 receptor antagonists, methods for production and use thereof," which focuses on novel substituted methyl-amines that serve as crucial components within pharmaceutical compositions for preventing and treating CNS diseases. The invention details the general formula 1, highlighting various components such as different cyclic structures and substituents that form the basis for the active compounds.
Another notable patent is "Substituted 3-arylsulfonyl-pyrazolo[1,5-a]pyrimidines, serotonin 5-HT6 receptor antagonists and methods for the production and use thereof." This patent presents a novel approach to developing 3-arylsulfonyl-pyrazolo-pyrimidines designed for treating serious diseases associated with serotonin 5-HT receptors, such as Alzheimer’s disease, Parkinson’s disease, and cognitive disorders, showcasing the therapeutic potential of her inventions.
Career Highlights: Throughout her career, Madina has demonstrated a profound commitment to advancing scientific knowledge in the area of serotonin-related pharmacology. Her patents not only highlight her inventive capabilities but also underline the importance of her research in combating neurodegenerative diseases.
Collaborations: Madina has collaborated with prominent colleagues, including Oleg Dmitrievich Mitkin and Alexandre Vasilievich Ivachtchenko, who share her dedication to exploring new therapeutic avenues in neuroscience. Their teamwork exemplifies the collaborative spirit that fuels groundbreaking innovations within the scientific community.
Conclusion: As an accomplished inventor, Madina Georgievna Kadieva continues to push the boundaries of pharmaceutical science, particularly in the realm of central nervous system disorders. Her patents reflect her innovative spirit and commitment to improving health outcomes through scientific research and invention.